- Home
- REAL vs NTLA Comparison
REAL vs NTLA Comparison
Compare REAL & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAL
- NTLA
- Stock Information
- Founded
- REAL 2011
- NTLA 2014
- Country
- REAL United States
- NTLA United States
- Employees
- REAL N/A
- NTLA N/A
- Industry
- REAL Other Specialty Stores
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- REAL Consumer Discretionary
- NTLA Health Care
- Exchange
- REAL Nasdaq
- NTLA Nasdaq
- Market Cap
- REAL 1.2B
- NTLA 959.4M
- IPO Year
- REAL 2019
- NTLA 2016
- Fundamental
- Price
- REAL $9.15
- NTLA $10.17
- Analyst Decision
- REAL Buy
- NTLA Buy
- Analyst Count
- REAL 6
- NTLA 18
- Target Price
- REAL $7.04
- NTLA $50.53
- AVG Volume (30 Days)
- REAL 2.9M
- NTLA 3.2M
- Earning Date
- REAL 02-27-2025
- NTLA 02-20-2025
- Dividend Yield
- REAL N/A
- NTLA N/A
- EPS Growth
- REAL N/A
- NTLA N/A
- EPS
- REAL N/A
- NTLA N/A
- Revenue
- REAL $579,862,000.00
- NTLA $43,086,000.00
- Revenue This Year
- REAL $11.27
- NTLA $50.68
- Revenue Next Year
- REAL $9.11
- NTLA N/A
- P/E Ratio
- REAL N/A
- NTLA N/A
- Revenue Growth
- REAL 2.52
- NTLA N/A
- 52 Week Low
- REAL $1.52
- NTLA $9.25
- 52 Week High
- REAL $11.38
- NTLA $34.87
- Technical
- Relative Strength Index (RSI)
- REAL 50.80
- NTLA 43.03
- Support Level
- REAL $8.65
- NTLA $9.32
- Resistance Level
- REAL $10.14
- NTLA $10.73
- Average True Range (ATR)
- REAL 0.54
- NTLA 0.63
- MACD
- REAL -0.11
- NTLA 0.08
- Stochastic Oscillator
- REAL 33.56
- NTLA 41.63
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the us, generating $1.7 billion in 2023 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 34% of net merchandise value, which excludes returns, cancellations, and first-party sales.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.